ABSTRACT
Nanoparticle (NP)-based mRNA cancer vaccines hold great promise to realize personalized cancer treatments. To advance this technology requires delivery formulations for efficient intracellular delivery to antigen-presenting cells. We developed a class of bioreducible lipophilic poly(beta-amino ester) nanocarriers with quadpolymer architecture. The platform is agnostic to the mRNA sequence, with one-step self-assembly allowing for delivery of multiple antigen-encoding mRNAs as well as codelivery of nucleic acid-based adjuvants. We examined structure-function relationships for NP-mediated mRNA delivery to dendritic cells (DCs) and identified that a lipid subunit of the polymer structure was critical. Following intravenous administration, the engineered NP design facilitated targeted delivery to the spleen and preferential transfection of DCs without the need for surface functionalization with targeting ligands. Treatment with engineered NPs codelivering antigen-encoding mRNA and toll-like receptor agonist adjuvants led to robust antigen-specific CD8+ T cell responses, resulting in efficient antitumor therapy in in vivo models of murine melanoma and colon adenocarcinoma.
Subject(s)
Adenocarcinoma , Cancer Vaccines , Colonic Neoplasms , Nanoparticles , Animals , Mice , Humans , Dendritic Cells , Spleen , Ligands , RNA, Messenger/genetics , Adenocarcinoma/pathology , Colonic Neoplasms/therapy , Colonic Neoplasms/pathology , Antigens , Adjuvants, Immunologic , Vaccination , Nanoparticles/chemistry , Polymers/chemistryABSTRACT
Clinical translation of polymer-based nanocarriers for systemic delivery of RNA has been limited due to poor colloidal stability in the blood stream and intracellular delivery of the RNA to the cytosol. To address these limitations, this study reports a new strategy incorporating photocrosslinking of bioreducible nanoparticles for improved stability extracellularly and rapid release of RNA intracellularly. In this design, the polymeric nanocarriers contain ester bonds for hydrolytic degradation and disulfide bonds for environmentally triggered small interfering RNA (siRNA) release in the cytosol. These photocrosslinked bioreducible nanoparticles (XbNPs) have a shielded surface charge, reduced adsorption of serum proteins, and enable superior siRNA-mediated knockdown in both glioma and melanoma cells in high-serum conditions compared to non-crosslinked formulations. Mechanistically, XbNPs promote cellular uptake and the presence of secondary and tertiary amines enables efficient endosomal escape. Following systemic administration, XbNPs facilitate targeting of cancer cells and tissue-mediated siRNA delivery beyond the liver, unlike conventional nanoparticle-based delivery. These attributes of XbNPs facilitate robust siRNA-mediated knockdown in vivo in melanoma tumors colonized in the lungs following systemic administration. Thus, biodegradable polymeric nanoparticles, via photocrosslinking, demonstrate extended colloidal stability and efficient delivery of RNA therapeutics under physiological conditions, and thereby potentially advance systemic delivery technologies for nucleic acid-based therapeutics.
ABSTRACT
The recently described genus Paragalago is a complex of several nocturnal and morphologically cryptic species distributed in the forests of eastern Africa. Species diversity within this genus has been mainly described using species-specific differences in their loud calls. However, molecular data are still lacking for this group and species boundaries remain unclear. In this study, we explore species diversity within the zanzibaricus-complex using a combination of mitochondrial and nuclear data and comparing multiple species delimitation methods. Our results consistently support the existence of three independent lineages, P. cocos, P. zanzibaricus, and P. granti, confirming previous hypotheses based on vocal data. We conclude that these three lineages represent valid cryptic species and we hypothesize that speciation within this complex was characterized by cycles of forest expansion and contraction in the Plio-Pleistocene.
Subject(s)
Galagidae/classification , Animals , Bayes Theorem , Cytochromes b/genetics , Forests , Galagidae/anatomy & histology , Galagidae/genetics , Mitochondria/genetics , Phylogeny , Species SpecificityABSTRACT
Recombinant factor VIIa (FVIIa) variants with increased activity offer the promise to improve the treatment of bleeding episodes in patients with inhibitor-complicated hemophilia. Here, an approach was adopted to enhance the activity of FVIIa by selectively optimizing substrate turnover at the membrane surface. Under physiological conditions, endogenous FVIIa engages its cell-localized cofactor tissue factor (TF), which stimulates activity through membrane-dependent substrate recognition and allosteric effects. To exploit these properties of TF, a covalent complex between FVIIa and the soluble ectodomain of TF (sTF) was engineered by introduction of a nonperturbing cystine bridge (FVIIa Q64C-sTF G109C) in the interface. Upon coexpression, FVIIa Q64C and sTF G109C spontaneously assembled into a covalent complex with functional properties similar to the noncovalent wild-type complex. Additional introduction of a FVIIa-M306D mutation to uncouple the sTF-mediated allosteric stimulation of FVIIa provided a final complex with FVIIa-like activity in solution, while exhibiting a two to three orders-of-magnitude increase in activity relative to FVIIa upon exposure to a procoagulant membrane. In a mouse model of hemophilia A, the complex normalized hemostasis upon vascular injury at a dose of 0.3 nmol/kg compared with 300 nmol/kg for FVIIa.
Subject(s)
Biological Therapy/methods , Factor VIIa/chemistry , Hemophilia A/therapy , Protein Engineering/methods , Thromboplastin/chemistry , Allosteric Regulation , Animals , Blood Coagulation/drug effects , Disease Models, Animal , Factor VIIa/genetics , Factor VIIa/pharmacology , Factor VIIa/therapeutic use , Female , Hemophilia A/physiopathology , Humans , Kinetics , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Molecular Dynamics Simulation , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/pharmacology , Recombinant Proteins/therapeutic use , Thromboplastin/genetics , Thromboplastin/pharmacology , Thromboplastin/therapeutic useABSTRACT
Describing primate biodiversity is one of the main goals in primatology. Species are the fundamental unit of study in phylogeny, behaviour, ecology and conservation. Identifying species boundaries is particularly challenging for nocturnal taxa where only subtle morphological variation is present. Traditionally, vocal signals have been used to identify species within nocturnal primates: species-specific signals often play a critical role in mate recognition, and they can restrict gene flow with other species. However, little research has been conducted to test whether different "acoustic forms" also represent genetically distinct species. Here, we investigate species boundaries between two putative highly cryptic species of Eastern dwarf galagos (Paragalago cocosand P. zanzibaricus). We combined vocal and genetic data: molecular data included the complete mitochondrial cytochrome b gene (1,140 bp) for 50 samples across 11 localities in Kenya and Tanzania, while vocal data comprised 221 vocalisations recorded across 8 localities. Acoustic analyses showed a high level of correct assignation to the putative species (approx. 90%), while genetic analyses identified two separate clades at the mitochondrial level. We conclude that P. cocos and P. zanzibaricus represent two valid cryptic species that probably underwent speciation in the Late Pliocene while fragmented in isolated populations in the eastern forests.
Subject(s)
DNA, Mitochondrial/analysis , Galago/classification , Phylogeny , Vocalization, Animal/classification , Animals , Cytochromes b/analysis , Galago/genetics , Galago/physiology , Genes, Mitochondrial , Haplotypes , Kenya , TanzaniaABSTRACT
Breastfeeding is one of the foundations of child health, development and survival. Breastmilk substitutes (BMS) are associated with negative influences on breastfeeding practices and subsequent health concerns and, as with all foods, production and consumption of BMS comes with an environmental cost. The carbon footprint (CFP) of production and consumption of BMS was estimated in this study. To illustrate regional differences among the largest producers and consumers, the CFP of BMS production in New Zealand, United States (USA), Brazil and France and the CFP of BMS consumption in United Kingdom (UK), China, Brazil and Vietnam were assessed. The CFP values were then compared with the CFP of breastfeeding arising from production of the additional food needed for breastfeeding mothers to maintain energy balance (approximately 500â¯kcal per day). The CFP of production was estimated to be 9.2⯱â¯1.4, 7.0⯱â¯1.0, 11⯱â¯2 and 8.4⯱â¯1.3â¯kg CO2e per kg BMS in New Zealand, USA, Brazil and France, respectively, with the largest contribution (68-82% of the total) coming from production of raw milk. The CFP of consumption, which included BMS production, emissions from transport, production and in-home sterilisation of bottles, and preparation of BMS, was estimated to be 11⯱â¯1, 14⯱â¯2, 14⯱â¯2 and 11⯱â¯1â¯kg CO2e per kg BMS in UK, China, Brazil and Vietnam, respectively. Comparison of breastfeeding with feeding BMS showed a lower CFP from breastfeeding in all countries studied. However, the results were sensitive to the method used to allocate emissions from raw milk production on different dairy processing co-products (i.e. BMS, cream, cheese and lactose). Using alternative allocation methods still resulted in lower CFP from breastfeeding, but only slightly for UK, Brazil and Vietnam. Care is also needed when interpreting findings about products that are functionally different as regards child health and development.
ABSTRACT
OBJECTIVE: To determine the relationship between changes in antibody levels towards citrullinated peptides derived from different candidate autoantigens and therapeutic outcome in early rheumatoid arthritis (RA). METHODS: Baseline and 3-month serum samples from 316 patients with early RA enrolled in the Swedish Farmacotherapy (SWEFOT) trial were analysed for antibodies against cyclic citrullinated peptides (CCP) and citrullinated peptides derived from vimentin (cVim), fibrinogen (cFib) and α-enolase (CEP-1). At 3-month follow-up, methotrexate monotherapy-inadequate responders were randomised to add-on therapy with sulfasalazine and hydroxychloroquine or infliximab. In these patients, anticitrullinated peptide antibodies (ACPA) were also assessed at 12 and 24â months. The proportion of antibody-positive patients and relative changes in antibody levels were compared across ACPA specificities and related to therapeutic response and radiographic progression. RESULTS: During the 2-year follow-up, the proportion of patients testing positive declined significantly regarding antibodies to cVim, cFib and CEP-1, while anti-CCP antibody occurrence remained stable over time. Turning anti-cVim antibody negative was most common, and anti-cVim antibody seroreversion during the first threeâ months associated with significantly less 2-year radiographic progression compared with patients who remained positive. Median antibody levels of all tested ACPAs declined uniformly during initial methotrexate therapy and following response to add-on therapy, with no significant relation to treatment regimen or radiographic progression. CONCLUSIONS: The influence of early antirheumatic therapy on ACPA seroreversions was markedly different across specificities, and early disappearance of anti-cVim antibodies associated with better radiological outcome. Thus, these data suggest that the disappearance of particular ACPA reactivities may be beneficial in early RA. TRIAL REGISTRATION NUMBER: WHO database at the Karolinska institute: CT20080004; and clinicaltrials.gov: NCT00764725.
Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/immunology , Autoantibodies/blood , Methotrexate/therapeutic use , Peptides, Cyclic/immunology , Antibody Specificity , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/diagnostic imaging , Autoantibodies/drug effects , Disease Progression , Drug Therapy, Combination , Female , Fibrinogen/immunology , Humans , Hydroxychloroquine/therapeutic use , Infliximab/therapeutic use , Male , Middle Aged , Phosphopyruvate Hydratase/immunology , Radiography , Sulfasalazine/therapeutic use , Sweden , Vimentin/immunologyABSTRACT
MOTIVATION: Modeling of dynamical systems using ordinary differential equations is a popular approach in the field of Systems Biology. The amount of experimental data that are used to build and calibrate these models is often limited. In this setting, the model parameters may not be uniquely determinable. Structural or a priori identifiability is a property of the system equations that indicates whether, in principle, the unknown model parameters can be determined from the available data. RESULTS: We performed a case study using three current approaches for structural identifiability analysis for an application from cell biology. The approaches are conceptually different and are developed independently. The results of the three approaches are in agreement. We discuss strength and weaknesses of each of them and illustrate how they can be applied to real world problems. AVAILABILITY AND IMPLEMENTATION: For application of the approaches to further applications, code representations (DAISY, Mathematica and MATLAB) for benchmark model and data are provided on the authors webpage. CONTACT: andreas.raue@fdm.uni-freiburg.de.
Subject(s)
Systems Biology/methods , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Humans , Interleukin-13/pharmacology , Lymphoma/genetics , Models, Biological , RNA, Messenger/biosynthesis , Research DesignABSTRACT
OBJECTIVE: To estimate the incremental cost-effectiveness of infliximab versus conventional combination treatment over 21â months in patients with methotrexate-refractory early rheumatoid arthritis. METHODS: In this multicentre, two-arm, parallel, randomised, active-controlled, open-label trial, rheumatoid arthritis patients with <1â year symptom duration were recruited from 15 rheumatology clinics in Sweden between October 2002 and December 2005. After 3-4â months of methotrexate monotherapy, patients not achieving low disease activity were randomised to addition of infliximab or sulfasalazine+hydroxychloroquine (conventional treatment group). Costs of drugs, healthcare use, and productivity losses were retrieved from nationwide registers, while EuroQol 5-Dimensions utility was collected quarterly. RESULTS: Of 487 patients initially enrolled, 128 and 130 were randomised to infliximab and conventional treatment, respectively. The infliximab group accumulated higher drug and healthcare costs (27,487 vs 10,364; adjusted mean difference 16,956 (95% CI 14,647 to 19,162)), while productivity losses did not differ (33,804 vs 29,220; 3961 (95% CI -3986 to 11,850)), resulting in higher societal cost compared to the conventional group (61,291 vs 39,584; 20,916 (95% CI 12,800 to 28,660)). Mean accumulated quality-adjusted life-years (QALYs) did not differ (1.10 vs 1.12; adjusted mean difference favouring infliximab treatment 0.01 (95% CI -0.07 to 0.08)). The incremental cost-effectiveness ratios for the infliximab versus conventional treatment strategy were 2,404,197/QALY from the societal perspective and 1,948,919/QALY from the healthcare perspective. CONCLUSIONS: In early, methotrexate-refractory rheumatoid arthritis, a treatment strategy commencing with addition of infliximab, as compared to sulfasalazine+hydroxychloroquine, was not cost-effective over 21â months at willingness to pay levels generally considered acceptable. TRIAL REGISTRATION NUMBER: NCT00764725.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Hydroxychloroquine/therapeutic use , Sulfasalazine/therapeutic use , Adult , Aged , Antibodies, Monoclonal/economics , Antirheumatic Agents/economics , Arthritis, Rheumatoid/economics , Cost-Benefit Analysis , Drug Costs , Drug Therapy, Combination , Female , Health Care Costs , Health Services/economics , Health Services/statistics & numerical data , Humans , Hydroxychloroquine/economics , Infliximab , Male , Methotrexate/therapeutic use , Middle Aged , Quality-Adjusted Life Years , Sick Leave/economics , Sulfasalazine/economics , Treatment Failure , Treatment OutcomeABSTRACT
Many substances are hepatotoxic due to their ability to cause intrahepatic cholestasis. Therefore, there is a high demand for in vitro systems for the identification of cholestatic properties of new compounds. Primary hepatocytes cultivated in collagen sandwich cultures are known to establish bile canaliculi which enclose secreted biliary components. Cholestatic compounds are mainly known to inhibit bile excretion dynamics, but may also alter canalicular volume, or hepatocellular morphology. So far, techniques to assess time-resolved morphological changes of bile canaliculi in sandwich cultures are not available. In this study, we developed an automated system that quantifies dynamics of bile canaliculi recorded in conventional time-lapse image sequences. We validated the hepatocyte sandwich culture system as an appropriate model to study bile canaliculi in vitro by showing structural similarity measured as bile canaliculi length per hepatocyte to that observed in vivo. Moreover, bile canalicular excretion kinetics of CMFDA (5-chloromethylfluorescein diacetate) in sandwich cultures resembled closely the kinetics observed in vivo. The developed quantification technique enabled the quantification of dynamic changes in individual bile canaliculi. With this technique, we were able to clearly distinguish between sandwich cultures supplemented with dexamethasone and insulin from control cultures. In conclusion, the automated quantification system offers the possibility to systematically study the causal relationship between disturbed bile canalicular dynamics and cholestasis.
Subject(s)
Bile Canaliculi/drug effects , Cell Culture Techniques , Collagen/chemistry , Hepatocytes/drug effects , Animals , Bile Canaliculi/metabolism , Cells, Cultured , Chemical and Drug Induced Liver Injury/diagnosis , Cholestasis, Intrahepatic/chemically induced , Dexamethasone/administration & dosage , Fluoresceins/pharmacokinetics , Hepatocytes/metabolism , Insulin/administration & dosage , Male , Mice , Mice, Inbred C57BLABSTRACT
An attractive approach in implant technology is local drug delivery, and design of efficient, safe and reliable treatments. Our hitherto strategy has been to coat Ti implants with a thin mesoporous TiO2 film that in turn is loaded with an osteoporosis drug, such as Alendronate (ALN) that is known to suppress osteoclastic activity. This system has proven highly successful and results in excellent osseointegration. However, more detailed information about drug-release and distribution at the bone/implant interface is needed. In this study, (14)C-ALN loaded titanium implants were placed up to 8 weeks into rat tibia and the spatial-temporal distribution of the drug was evaluated. Autoradiography data demonstrated a sustained release of (14)C-ALN and the released drug remained bound to bone in close vicinity, within 500 micrometers, of the implants. Liquid scintillation counting experiments confirmed that the distal transport of released (14)C-ALN was extremely low. The results are favorable as they show that ALN stays for a long time in the vicinity of the implant and may therefore improve for a long time the mechanical fixation of bone anchored implants. Moreover, these findings suggest due to the low systemic spreading a minimal risk of Alendronate related systemic side effects.
Subject(s)
Alendronate/metabolism , Bone and Bones/metabolism , Dental Implants , Titanium , Animals , In Vitro Techniques , Male , Rats , Rats, Sprague-DawleyABSTRACT
In the field of biomedical technology, a critical aspect is the ability to control and understand the integration of an implantable device in living tissue. Despite the technical advances in the development of biomaterials, the elaborate interplay encompassing materials science and biology on the atomic level is not very well understood. Within implantology, anchoring a biomaterial device into bone tissue is termed osseointegration. In the most accepted theory, osseointegration is defined as an interfacial bonding between implant and bone; however, there is lack of experimental evidence to confirm this. Here we show that atom probe tomography can be used to study the implant-tissue interaction, allowing for three-dimensional atomic mapping of the interface region. Interestingly, our analyses demonstrated that direct contact between Ca atoms and the implanted titanium oxide surface is formed without the presence of a protein interlayer, which means that a pure inorganic interface is created, hence giving experimental support to the current theory of osseointegration. We foresee that this result will be of importance in the development of future biomaterials as well as in the design of in vitro evaluation techniques.
Subject(s)
Dental Implants , Microscopy, Atomic Force , Osseointegration , Dental Implantation, Endosseous , HumansABSTRACT
Identifying active compounds for a target is a time- and resource-intensive task in early drug discovery. Accurate bioactivity prediction using morphological profiles could streamline the process, enabling smaller, more focused compound screens. We investigate the potential of deep learning on unrefined single-concentration activity readouts and Cell Painting data, to predict compound activity across 140 diverse assays. We observe an average ROC-AUC of 0.744 ± 0.108 with 62% of assays achieving ≥0.7, 30% ≥0.8, and 7% ≥0.9. In many cases, the high prediction performance can be achieved using only brightfield images instead of multichannel fluorescence images. A comprehensive analysis shows that Cell Painting-based bioactivity prediction is robust across assay types, technologies, and target classes, with cell-based assays and kinase targets being particularly well-suited for prediction. Experimental validation confirms the enrichment of active compounds. Our findings indicate that models trained on Cell Painting data, combined with a small set of single-concentration data points, can reliably predict the activity of a compound library across diverse targets and assays while maintaining high hit rates and scaffold diversity. This approach has the potential to reduce the size of screening campaigns, saving time and resources, and enabling primary screening with more complex assays.
Subject(s)
Drug Discovery , High-Throughput Screening Assays , High-Throughput Screening Assays/methods , Humans , Drug Discovery/methods , Deep Learning , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacologyABSTRACT
Comprehensive but interpretable assessment of the environmental performance of diets involves choosing a set of appropriate indicators. Current knowledge and data gaps on the origin of dietary foodstuffs restrict use of indicators relying on site-specific information. This Personal View summarises commonly used indicators for assessing the environmental performance of diets, briefly outlines their benefits and drawbacks, and provides recommendations on indicator choices for actors across multiple fields involved in activities that include the environmental assessment of diets. We then provide recommendations on indicator choices for actors across multiple fields involved in activities that use environmental assessments, such as health and nutrition experts, policy makers, decision makers, and private-sector and public-sector sustainability officers. We recommend that environmental assessment of diets should include indicators for at least the five following areas: climate change, biosphere integrity, blue water consumption, novel entities, and impacts on natural resources (especially wild fish stocks), to capture important environmental trade-offs. If more indicators can be handled in the assessment, indicators to capture impacts related to land use quantity and quality and green water consumption should be used. For ambitious assessments, indicators related to biogeochemical flows, stratospheric ozone depletion, and energy use can be added.
Subject(s)
DietABSTRACT
OBJECTIVE: To compare EuroQol 5-Dimensions (EQ-5D) utility and quality-adjusted life-years (QALYs) in patients with early, methotrexate (MTX) refractory rheumatoid arthritis (RA), randomised to addition of infliximab (IFX) or sulfasalazine and hydroxychloroquine (SSZ+HCQ). METHODS: RA-patients with symptoms <1 year were enrolled between 2002 and 2005 at 15 Swedish centres. After 3-4 months of MTX monotherapy, patients with a remaining DAS28>3.2 were randomised to addition of IFX or SSZ+HCQ and followed for 21 months. EQ-5D profiles were collected every 3 months. Between-group comparisons of utility change and accumulated QALYs were performed, using last observation carried forward (LOCF) following protocol breach. Missing data were imputed by linear interpolation or LOCF. Sensitivity analyses applying baseline observation carried forward (BOCF) or restricted to completers were conducted. RESULTS: Of 487 patients initially enrolled, 128 and 130 were randomised to IFX or SSZ+HCQ, respectively. Mean utility in the IFX and SSZ+HCQ groups increased from 0.52 (SD 0.27) and 0.55 (SD 0.27) at randomisation to 0.66 (SD 0.25) and 0.63 (SD 0.27) at 21 months (adjusted mean difference favouring IFX 0.04; 95% CI -0.01, 0.09; p=0.15). Average accumulated QALYs were 1.10 (SD 0.37) and 1.07 (SD 0.42) in the IFX and SSZ+HCQ groups, respectively (adjusted mean difference favouring IFX 0.07; 95%CI -0.01, 0.14; p=0.07). BOCF analysis showed similar results, while differences were reversed, though remained statistically non-significant among completers. Dropout rates in the IFX/SSZ+HCQ groups were 30%/43% (p=0.01). CONCLUSIONS: Comparing addition of IFX or SSZ+HCQ to MTX in active early RA, no statistically significant differences in utility or QALY gain could be detected over 21 months. TRIAL REGISTRATION: Registered in WHO database at the Karolinska University Hospital, number CT20080004.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Hydroxychloroquine/therapeutic use , Methotrexate/therapeutic use , Sulfasalazine/therapeutic use , Adult , Aged , Arthritis, Rheumatoid/rehabilitation , Drug Therapy, Combination , Female , Humans , Immunosuppressive Agents , Infliximab , Kaplan-Meier Estimate , Male , Middle Aged , Quality of Life , Quality-Adjusted Life Years , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitorsABSTRACT
Multistatic active sonar systems involve the transmission and reception of multiple probing sequences and can achieve significantly enhanced performance of target detection and localization through exploiting spatial diversity. This paper mainly focuses on two signal processing aspects of such systems, namely, enhanced range-Doppler imaging and improved target parameter estimation. The main contributions of this paper are (1) a hybrid dense-sparse method is proposed to generate range-Doppler images with both low sidelobe levels and high accuracy; (2) a generalized K-Means clustering (GKC) method for target association is developed to associate the range measurements from different transmitter-receiver pairs, which is actually a range fitting procedure; (3) the extended invariance principle-based weighted least-squares method is developed for accurate target position and velocity estimation. The effectiveness of the proposed multistatic active sonar signal processing techniques is verified using numerical examples.
ABSTRACT
Immuno-oncology therapies have been of great interest with the goal of inducing sustained tumor regression, but clinical results have demonstrated the need for improved and widely applicable methods. An antigen-free method of cancer immunotherapy can stimulate the immune system to recruit lymphocytes and produce immunostimulatory factors without prior knowledge of neoantigens, while local delivery reduces the risk of systemic toxicity. To improve the interactions between tumor cells and cytotoxic lymphocytes, a gene delivery nanoparticle platform was engineered to reprogram the tumor microenvironment (TME) in situ to be more immunostimulatory by inducing tumor-associated antigen-presenting cells (tAPCs) to activate cytotoxic lymphocytes against the tumor. Biodegradable, lipophilic poly (beta-amino ester) (PBAE) nanoparticles were synthesized and used to co-deliver mRNA constructs encoding a signal 2 co-stimulatory molecule (4-1BBL) and a signal 3 immuno-stimulatory cytokine (IL-12), along with a nucleic acid-based immunomodulatory adjuvant. Nanoparticles are combined with a thermoresponsive block copolymer for gelation at the injection site for local NP retention at the tumor. The reprogramming nanoparticle gel synergizes with immune checkpoint blockade (ICB) to induce tumor regression and clearance in addition to resistance to tumor rechallenge at a distant site. In vitro and in vivo studies reveal increases in immunostimulatory cytokine production and recruitment of immune cells as a result of the nanoparticles. Intratumoral injection of nanoparticles encapsulating mRNA encoding immunostimulatory agents and adjuvants via an injectable thermoresponsive gel has great translational potential as an immuno-oncology therapy that can be accessible to a wide range of patients.
Subject(s)
Antineoplastic Agents , Nanoparticles , Neoplasms , Humans , RNA, Messenger/genetics , Antineoplastic Agents/pharmacology , Polymers/pharmacology , Adjuvants, Immunologic/pharmacology , Neoplasms/therapy , Interleukin-12 , Tumor MicroenvironmentABSTRACT
The productivity of any scientist is affected by cumbersome, tedious and time-consuming tasks that try to make the heterogeneous web services compatible so that they can be useful in their research. MOWServ, the bioinformatic platform offered by the Spanish National Institute of Bioinformatics, was released to provide integrated access to databases and analytical tools. Since its release, the number of available services has grown dramatically, and it has become one of the main contributors of registered services in the EMBRACE Biocatalogue. The ontology that enables most of the web-service compatibility has been curated, improved and extended. The service discovery has been greatly enhanced by Magallanes software and biodataSF. User data are securely stored on the main server by an authentication protocol that enables the monitoring of current or already-finished user's tasks, as well as the pipelining of successive data processing services. The BioMoby standard has been greatly extended with the new features included in the MOWServ, such as management of additional information (metadata such as extended descriptions, keywords and datafile examples), a qualified registry, error handling, asynchronous services and service replication. All of them have increased the MOWServ service quality, usability and robustness. MOWServ is available at http://www.inab.org/MOWServ/ and has a mirror at http://www.bitlab-es.com/MOWServ/.
Subject(s)
Computational Biology , Software , Databases, Protein , Internet , Phylogeny , Proteins/chemistry , Proteins/classification , Systems IntegrationABSTRACT
This study aimed at exploring and describing the self-care management strategies used by patients with coronary artery disease to facilitate sleep. Qualitative interviews in a dialogue manner, in a phenomenographic reference frame analyzed according to manifest and latent principles of qualitative content analysis, were performed. A purposeful sampling technique was used including 11 patients with coronary heart disease in a Heart Medical Unit in a general hospital setting. Two main themes were identified: 'sleep-rhythm' and 'sleep-hygiene' including four descriptive categories. The categories reveal five basic responses including emotions, cognition, physical symptoms (reactions), behaviours and/or the sleep environment, which were related to perceived or actual presence of sleep-wake problems and health that were the underlying reason for the self-care management strategies. Basically, intervention studies that address these five responses for choice of non-pharmacological methods based on cognitive behavioural therapy provided by nurses are needed.
Subject(s)
Heart Diseases/physiopathology , Self Care , Sleep , Adult , Aged , Female , Humans , Male , Middle AgedABSTRACT
To balance trade-offs between livestock's negative environmental impacts and their positive contributions (e.g. maintaining semi-natural grasslands, varied agricultural landscapes and crop rotations), a better understanding is needed of how the supply of ecosystem services differs across farms. We analysed a suite of indicators for non-provisioning ecosystem services on a large subset of Swedish farms (71% of farms, covering 82% of agricultural land) and related these to farm type, farm size and livestock density. The analysed indicators exhibited clear geographical patterns with hotspots especially in less productive regions. Controlling for this spatial variation we still found that small-scale and ruminant farms were associated with more varied landscapes, small-scale habitats, semi-natural grasslands and better crop sequences compared to nearby farms specialised in crop production, while farms specialising in monogastric livestock were associated with less varied landscapes and inferior crop sequences. Results for cultural ecosystem services indicated that farms with more semi-natural grassland were associated with more visitors and more likely located within designated recreation or nature conservation areas.